The increased levels of GSTO1 and PRDX6 in plasma of lung cancer patients may reflect their protective role in the cancer redox environment, or may be associated with the activation of antioxidant pathways resulting from cigarette smoking. Here, PRDX6 is linked to lung carcinoma.